Stock listing
NASDAQ:CYCN Cyclerion Therapeutics, Inc. Stock
Home listing (NASDAQ) of Cyclerion Therapeutics, Inc.
Follow Cyclerion Therapeutics, Inc. into a list and get an email when it puts out news.

- Ticker
- NASDAQ:CYCN
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Apr 1, 2026
Cyclerion Therapeutics and Korsana Biosciences Announce Merger Agreement
Latest deck · July 2026
Korsana Biosciences — Merger or Acquisition (July 2026)
Merger or acquisition · 32 slides
Latest news
Cyclerion Therapeutics, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 3 in the last 12 months · 47 in all · newest Apr 1, 2026 · oldest 2019
- Decks
- 22 decks · latest July 2026
Where Cyclerion Therapeutics, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:CYCN · Home listing · This page | NASDAQ | United States | USD |
| BOATS:CYCN | BOATS | United States | USD |
Valuation
Statements: Year to Dec 31, 2025 · balance Sep 30, 2026
- Enterprise value
- No market cap
- P/E
- No market cap
- EV/sales
- No market cap
- EV/EBITDA
- No market cap
- Price/book
- No market cap
- Gross margin
- 100.0%
- Operating margin
- −239.8%
- Net margin
- −170.1%
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 0.49
Forecasts
1 strong buy · Analysts' consensus from EODHD, read Nov 19, 2026. Not 6ix's view and not investment advice.
- Price target
- 56.00 USD · Analysts' mean
- EPS, year to Dec 2026
- -8.40 · 1 analyst
Team and board
Officers
| Officer | Role |
|---|---|
| Jonathan Violin | Chief Executive Officer |
| Mark Vignola | Chief Financial Officer |
| Eva Stroynowski | VP, Investor Relations |
| Angela She | VP, R&D Strategy and Operations |
| Joshua Park | VP, Protein Sciences |
| Kyle Breidenstine | SVP, Finance |
| Maribel Reyes | VP, Clinical Pharmacology and Translational Science |
| Michael Oldham | VP, Clinical Development |
| Robin Wojcieszek | SVP, Regulatory, Drug Safety and Medical Writing |
| Vanessa Teachout | VP, Head of Clinical Operations |
| Gan Wei | Chief Technology Officer |
| Matthew Leoni | Chief Medical Officer |
Board
| Director | Role |
|---|---|
| Tomas Kiselak | Chairman |
| Andrew Gottesdiener | Director |
| Heidi Henson | Director |
| Jonathan Violin | Chief Executive Officer |
| Michelle Pernice | Director |
| Nimish Shah | Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q2 2026 | Aug 4, 2026 | +1.7% |
| Q4 2025 | Mar 31, 2026 · Before open | +7.3% |
| Q3 2025 | Nov 12, 2025 | −10.6% |
| Q2 2025 | Aug 5, 2025 | −14.2% |
| Q1 2025 | May 5, 2025 · After close | +1.3% |
| Q4 2024 | Mar 3, 2025 · After close | +9.6% |
| Q3 2024 | Nov 11, 2024 · After close | −23.4% |
| Q2 2024 | Aug 7, 2024 · Before open | −1.1% |
| Q1 2024 | May 7, 2024 · After close | +1.0% |
| Q4 2023 | Mar 5, 2024 · After close | −3.4% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q3 2023 | Nov 13, 2023 · After close | −9.1% |
| Q2 2023 | Jul 28, 2023 · After close | +14.2% |
| Q1 2023 | May 12, 2023 · Before open | −25.1% |
| Q4 2022 | Mar 22, 2023 · After close | −11.6% |
| Q3 2022 | Nov 3, 2022 · After close | −20.5% |
| Q2 2022 | Aug 9, 2022 · After close | +1.0% |
| Q1 2022 | May 4, 2022 · After close | −5.3% |
| Q4 2021 | Feb 24, 2022 · After close | −3.5% |
| Quarter to Sep 30, 2021 | Nov 9, 2021 · After close | −5.4% |
| Quarter to Jun 30, 2021 | Jul 29, 2021 · After close | −0.7% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Korsana Biosciences — Merger or Acquisition (July 2026) | Merger or acquisition | 32 slides | July 2026 |
| Merger or Acquisition (April 2026) | Merger or acquisition | 52 slides | Apr 1, 2026 |
| Merger or Acquisition (April 2026) | Merger or acquisition | 56 slides | Apr 1, 2026 |
| Korsana Biosciences — Merger or Acquisition (April 2026) | Merger or acquisition | 31 slides | April 2026 |
| Investor Presentation (February 2026) | Investor deck | 22 slides | Feb 17, 2026 |
| Korsana Biosciences — Investor Presentation (February 2026) | Investor deck | 28 slides | February 2026 |
| Investor Presentation (January 2026) | Investor deck | 28 slides | Jan 6, 2026 |
| Investor Presentation (January 2026) | Investor deck | 23 slides | January 2026 |
| Investor Presentation (January 2026) | Investor deck | 22 slides | January 2026 |
| Corporate Update (September 2025) | Corporate update | 15 slides | Sep 23, 2025 |
All 22 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Technical Presentation (July 2022) | Technical | 30 slides | Jul 28, 2022 |
| Investor Presentation (June 2022) | Investor deck | 63 slides | Jun 10, 2022 |
| Investor Presentation (September 2021) | Investor deck | 59 slides | Sep 30, 2021 |
| Investor Presentation (April 2021) | Investor deck | 59 slides | Apr 27, 2021 |
| Corporate Update (January 2021) | Corporate update | 37 slides | Jan 13, 2021 |
| Corporate Update (October 2020) | Corporate update | 24 slides | Oct 14, 2020 |
| Investor Presentation (July 2020) | Investor deck | 37 slides | Jul 9, 2020 |
| Corporate Update (July 2020) | Corporate update | 35 slides | Jul 9, 2020 |
| UMDF Power Surge 2020 | Conference | 7 slides | Jun 26, 2020 |
| Corporate Update (April 2020) | Corporate update | 35 slides | Apr 14, 2020 |
| J.P. Morgan Healthcare Conference 2020 | Conference | 16 slides | Jan 13, 2020 |
| Corporate Update (October 2019) | Corporate update | 17 slides | Oct 30, 2019 |
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.07M | 2.00M | 0 | 297.0K | 3.32M | 2.30M | 4.51M | 0 | 0 | 0 |
| Cost of revenue | 1.31M | 5.58M | 472.0K | 56.4M | 95.1M | 1.53M | 1.75M | 2.17M | ||
| Gross profit | 2.07M | 2.00M | -1.31M | -5.28M | 3.32M | -54.1M | -90.6M | -1.53M | -1.75M | -2.17M |
| Research and development | 959.0K | 286.0K | 1.51M | 5.98M | 37.6M | 56.4M | 95.1M | 87.7M | 78.8M | 50.9M |
| Selling, general and administrative | 6.09M | 5.34M | 8.13M | 12.9M | 20.6M | 28.8M | 34.4M | 27.5M | 15.1M | 12.7M |
| Operating income | -4.97M | -3.63M | -13.0M | -18.5M | -55.2M | -81.3M | -125.0M | -115.3M | -93.9M | -63.6M |
| Depreciation and amortization | 65.0K | 65.0K | 472.0K | 2.30M | 2.70M | 1.53M | 1.75M | 2.17M | ||
| EBITDA | -12.9M | -18.5M | -54.7M | -79.0M | -122.3M | -113.7M | -92.2M | -61.4M | ||
| Interest expense | 294.0K | 16.0K | 588.0K | 0 | 0 | 0 | 0 | |||
| Income before tax | -3.53M | -3.06M | -12.6M | -18.2M | -51.6M | -77.8M | -123.0M | -115.3M | -93.9M | -63.6M |
| Income tax | 8.42M | -294.0K | 16.0K | -5.13M | -2.03M | 1.37M | 0 | 0 | ||
| Net income | -3.53M | -3.06M | -5.26M | -44.1M | -51.6M | -77.8M | -123.0M | -115.3M | -93.9M | -63.6M |
| Earnings per share, basic | -7.66 | -8.50 | -15.76 | -141.99 | -184.72 | -358.26 | -628.97 | -590.94 | -481.58 | -324.71 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 3.24M | 3.23M | 7.57M | 13.4M | 54.0M | 54.4M | 97.6M | 0 | 0 | 0 |
| Short-term investments | 0 | 0 | 0 | |||||||
| Receivables | 1.00M | 556.0K | 0 | 96.0K | 100.0K | 127.0K | 1.47M | |||
| Inventory | 805.0K | 928.0K | 816.0K | 1.97M | 0 | 0 | 0 | |||
| Current assets | 4.63M | 4.22M | 8.02M | 14.8M | 55.5M | 58.5M | 101.2M | 879.0K | 1.26M | 275.0K |
| Property, plant and equipment | 1.22M | 1.47M | 6.87M | 79.8M | 6.50M | 4.13M | 3.60M | |||
| Goodwill | 0 | 0 | 0 | |||||||
| Total assets | 9.98M | 9.57M | 13.4M | 18.1M | 59.3M | 115.4M | 186.5M | 7.40M | 5.47M | 3.88M |
| Accounts payable | 508.0K | 390.0K | 1.20M | 2.97M | 1.83M | 1.15M | 3.31M | 2.78M | 1.80M | 1.41M |
| Current liabilities | 900.0K | 725.0K | 2.09M | 7.63M | 11.1M | 17.0M | 18.2M | 17.8M | 14.0M | 10.6M |
| Long-term debt | 0 | 0 | 0 | |||||||
| Total debt | 45.7M | 73.9M | ||||||||
| Total liabilities | 900.0K | 725.0K | 2.09M | 7.63M | 11.1M | 55.9M | 88.7M | 17.8M | 14.0M | 10.6M |
| Shareholders' equity | 9.09M | 8.85M | 11.3M | 10.5M | 48.2M | 59.5M | 97.7M | -10.4M | -8.57M | -6.76M |
| Shares outstanding | 460.7K | 359.7K | 334.0K | 310.4K | 279.6K | 217.2K | 195.6K | 195.0K | 195.0K | 195.7K |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -3.31M | -4.33M | -21.2M | -40.6M | -36.5M | -72.5M | -102.2M | -97.5M | -81.2M | -49.9M |
| Capital spending | 0 | 0 | 0 | 0 | -7.00K | -1.52M | -6.89M | -3.44M | -1.40M | -1.45M |
| Free cash flow | -3.31M | -4.33M | -21.2M | -40.6M | -36.5M | -74.0M | -109.1M | -100.9M | -82.6M | -51.3M |
| Cash from investing | 10.4M | 1.46M | 18.0K | -6.71M | -3.44M | -1.40M | -1.45M | |||
| Cash from financing | 3.32M | 0 | 5.02M | 29.0K | 30.8M | 28.1M | 211.6M | 100.9M | 82.6M | 51.3M |
| Dividends paid | 0 | 0 | 0 | |||||||
| Share buybacks | -130.0K | 0 | 24.6M | 165.1M | 0 | 0 | 0 | |||
| Change in cash | 8.00K | -4.34M | -5.81M | -40.6M | -4.27M | -44.4M | 102.6M | 102.6M | 102.6M | 102.6M |
Cap table
Built by 6ix from Cyclerion Therapeutics, Inc.’s releases
- Common shares
- 668,764
- Fully diluted
- 668,764
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 668,764 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 668,764 |
| Aug 26, 2026 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Terrance McGuire Other companies: Tectonic Therapeutic, Inc. (Director · Since at least Jun 20, 2024); Invivyd, Inc. (Director · Since at least Aug 5, 2021); Seer, Inc. (Director · Since at least Dec 3, 2020); Alector, Inc. (Director · Feb 6, 2019 – Sep 11, 2023 · Past); X4 Pharmaceuticals, Inc. (Director · Nov 15, 2017 – Jun 5, 2018 · Past); Pulmatrix, Inc. (Director · Jun 15, 2015 – May 16, 2019 · Past); Trevena, Inc. (Director · Jan 30, 2014 – May 14, 2014 · Past); Acceleron Pharma Inc (Director · Sep 18, 2013 – Mar 2, 2017 · Past); Ironwood Pharmaceuticals, Inc. (Director · Jun 3, 2013 – Apr 1, 2019 · Past) | Director · Apr 1, 2019 – Nov 30, 2023 · Past |
| Amy Schulman Other companies: Elevance Health, Inc. (Director · Since at least Dec 10, 2025); Fractyl Health, Inc. (Director · Since at least Feb 1, 2024); Alnylam Pharmaceuticals, Inc. (Chair of the Board · Since at least Jun 20, 2018); Hudson Executive Investment Corp II (Director · Jan 25, 2021 – Apr 13, 2021 · Past); Ironwood Pharmaceuticals, Inc. (Director · May 31, 2018 – Apr 1, 2019 · Past); Blue Buffalo Pet Products Inc (Director · Apr 24, 2018 – Apr 24, 2018 · Past); X4 Pharmaceuticals, Inc. (Director · Nov 15, 2017 – Jun 5, 2018 · Past) | Director · Apr 1, 2019 – Jun 16, 2020 · Past |
| Errol B Desouza Other companies: Alector, Inc. (Director · Since at least Mar 19, 2024); Royalty Pharma plc (Director · Jun 7, 2024 – May 13, 2025 · Past) | Director · Nov 30, 2023 – Nov 30, 2023 · Past |
| George H Conrades Other companies: Oracle Corporation (Director · Since at least May 31, 2018); Akamai Technologies, Inc. (Director · Dec 31, 2017 – May 20, 2018 · Past) | Director · Apr 1, 2019 – Jun 14, 2022 · Past |
| Andreas Busch Other companies: Absci Corporation (Chief Innovation Officer · Since at least Mar 17, 2022) | Chief Scientific Officer · Apr 29, 2019 – Jan 20, 2022 · Past |
| Cheryl Gault Other companies: Rapport Therapeutics, Inc. (Chief Operating Officer · Since at least Jun 6, 2024) | Chief Operating Officer · Jan 1, 2021 – Jan 20, 2022 · Past |
| Mark G Currie Other companies: Ironwood Pharmaceuticals, Inc. (Director · Since at least Jan 4, 2016) | President and CSO · Apr 1, 2019 – Dec 28, 2020 · Past |
| Michael Mendelsohn Other companies: Foghorn Therapeutics Inc. (Founder, Board Director, & Chief Strategy Officer, Cardurion Pharmaceuticals · Since at least Oct 22, 2020) | Director · Apr 1, 2019 – Jun 14, 2022 · Past |
| Rhonda M Chicko Other companies: Scholar Rock Holding Corporation (Chief Financial Officer · May 23, 2018 – Jan 31, 2019 · Past) | Chief Financial Officer · Since at least Mar 4, 2024 |
| Stephanie Lovell Other companies: TransMedics Group, Inc. (Director · Since at least Mar 22, 2021) | Director · Apr 1, 2019 – Jun 14, 2022 · Past |
All 29 people
| Person | Seat |
|---|---|
| Andrew Gottesdiener | Director · Since at least Apr 1, 2026 |
| Angela She | VP, R&D Strategy and Operations · Since at least Nov 4, 2026 |
| Eva Stroynowski | VP, Investor Relations · Since at least Nov 4, 2026 |
| Gan Wei | Chief Technology Officer · Since at least Nov 4, 2026 |
| Heidi Henson | Director · Since at least Nov 5, 2026 |
| Jonathan Violin | Chief Executive Officer · Since at least Apr 1, 2026 |
| Joshua Park | VP, Protein Sciences · Since at least Nov 4, 2026 |
| Kyle Breidenstine | SVP, Finance · Since at least Nov 4, 2026 |
| Maribel Reyes | VP, Clinical Pharmacology and Translational Science · Since at least Nov 4, 2026 |
| Mark Vignola | Chief Financial Officer · Since at least Nov 4, 2026 |
| Matthew Leoni | Chief Medical Officer · Since at least Nov 4, 2026 |
| Michael Oldham | VP, Clinical Development · Since at least Nov 4, 2026 |
| Michelle Pernice | Director · Since at least Apr 1, 2026 |
| Nimish Shah | Director · Since at least Apr 1, 2026 |
| Peter M Hecht | Director · Since at least Jul 16, 2026 |
| Regina Margaret Graul | See Remarks, Director · Since at least Aug 14, 2026 |
| Robin Wojcieszek | SVP, Regulatory, Drug Safety and Medical Writing · Since at least Nov 4, 2026 |
| Tomas Kiselak | Chairman · Since at least Apr 1, 2026 |
| Vanessa Teachout | VP, Head of Clinical Operations · Since at least Nov 4, 2026 |
Log in to ask 6ix AI your own questions about Cyclerion Therapeutics, Inc.